4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients.

ABSTRACT:

Objective

to evaluate the immune response to the SARS-CoV-2 vaccines in adults with immune-mediated rheumatic diseases (IMRDs) in comparison to healthy individuals, observed 1-20 weeks following the fourth vaccine dose. Additionally, to evaluate the impact of immunosuppressive therapies, vaccination schedules, the time interval between vaccination and sample collection on the vaccine's immune response.

Methods

We designed a longitudinal observational study conducted at the rheumatology department of Hospital de Copiapó. Neutralizing antibodies (Nabs) titers against the Wuhan and Omicron variant were analyzed between 1-20 weeks after administration of the fourth dose of the SARS-CoV-2 vaccine to 341 participants (218 IMRD patients and 123 healthy controls). 218 IMRD patients

SUBMITTER: Gallardo-Nelson MJ 

PROVIDER: S-EPMC11309998 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature